A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector

Virology

Volumn 377, Issue 2, 2008, Pages 379-390

  Wang, Z ^a   Zhou, W ^a   Srivastava, T ^a   La Rosa, C ^a   Mandarino, A ^a   Forman, S J ^a   Zaia, J A ^a   Britt, W J ^b   Diamond, D J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

Author keywords

Attenuated poxvirus; Cellular immunity; Human cytomegalovirus; Memory T cells; Regulatory proteins; Tegument protein; Transgenic mouse model; Viral vaccine

Indexed keywords

HYBRID PROTEIN; IE1 ANTIGEN; IE2 ANTIGEN; PP65 ANTIGEN; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXON; FUSION GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MODIFIED VACCINIA ANKARA; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANIMALS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS VACCINES; EXONS; GENETIC VECTORS; HUMANS; IMMEDIATE-EARLY PROTEINS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; MICE; PHOSPHOPROTEINS; VACCINIA; VIRAL FUSION PROTEINS; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 5; MUS MUSCULUS; POXVIRIDAE;

EID: 45049087865     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.04.034     Document Type: Article

References (81)

1. Antoine G., Scheiflinger F., Dorner F., and Falkner F.G. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244 (1998) 365-396
2. Avetisyan G., Aschan J., Hagglund H., Ringden O., and Ljungman P. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant 40 (2007) 865-869
3. Barouch D.H., McKay P.F., Sumida S.M., Santra S., Jackson S.S., Gorgone D.A., Lifton M.A., Chakrabarti B.K., Xu L., Nabel G.J., and Letvin N.L. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol. 77 (2003) 8729-8735
4. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., Kari L., Meric C., Cadoz M., Zahradnik J., Starr S., and Plotkin S. A canarypox vector-expressing cytomegalovirus (cmv) phosphoprotein 65 induces long-lasting cytotoxic t cell responses in human cmv-seronegative subjects. J. Infect. Dis. 183 (2001) 1171-1179
5. Blanchard T.J., Alcami A., Andrea P., and Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen.Virol. 79 Pt 5 (1998) 1159-1167
6. Boeckh M., Nakamura R., Cornelissen J.J., Zaia J.A., Forman S.J., Gaal K., Brooimans R.A., Gratama J.W., Gasior G.H., and Sullivan L.A. Immune monitoring with iTAg(TM) MHC tetramers for prediction of recurrent or persistent cytomegalovirus (CMV) infection in allogeneic stem cell transplant (SCT) recipients: a prospective multicenter clinical trial. Biol. Blood Marrow Transplant. 12 (2006) 79
7. Britt W.J., and Auger D. Identification of a 65 000 dalton virion envelope protein of human cytomegalovirus. Virus Res. 4 (1985) 31-36
8. Carroll M.W., and Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238 (1997) 198-211
9. Carroll M.W., Overwijk W.W., Chamberlain R.S., Rosenberg S.A., Moss B., and Restifo N.P. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 15 (1997) 387-394
10. Chakrabarti S., Sisler J.R., and Moss B. Compact, synthetic, vaccinia virus early/late promoter for protein expression. Biotechniques 23 (1997) 1094-1097
11. Cobbold M., Khan N., Pourgheysari B., Tauro S., McDonald D., Osman H., Assenmacher M., Billingham L., Steward C., Crawley C., Olavarria E., Goldman J., Chakraverty R., Mahendra P., Craddock C., and Moss P.A. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J. Exp. Med. 202 (2005) 379-386
12. Cosma A., Nagaraj R., Buhler S., Hinkula J., Busch D.H., Sutter G., Goebel F.D., and Erfle V. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22 (2003) 21-29
13. Cwynarski K., Ainsworth J., Cobbold M., Wagner S., Mahendra P., Apperley J., Goldman J., Craddock C., and Moss P.A. Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation. Blood 97 (2001) 1232-1240
14. Daftarian P., Ali S., Sharan R., Lacey S.F., La Rosa C., Longmate J., Buck C., Siliciano R.F., and Diamond D.J. Immunization with Th-CTL fusion peptide and cytosine-phosphate-guanine DNA in transgenic HLA-A2 mice induces recognition of HIV-infected T cells and clears vaccinia virus challenge. J. Immunol. 171 (2003) 4028-4039
15. Daftarian P., Sharan R., Haq W., Ali S., Longmate J., Termini J., and Diamond D.J. Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine 23 (2005) 3453-3468
16. de Waal L., Wyatt L.S., Yuksel S., van Amerongen G., Moss B., Niesters H.G., Osterhaus A.D., and de Swart R.L. Vaccination of infant macaques with a recombinant MVA expressing the RSV F and G genes does not predispose for immunopathology. Vaccine 22 (2004) 923-926
17. Diamond D.J., York J., Sun J., Wright C.L., and Forman S.J. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90 (1997) 1751-1767
18. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Montefiori D.C., Byrum R., Piatak M., Lifson J.D., Amara R.R., Robinson H.L., Huggins J.W., and Moss B. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 366 (2007) 84-97
19. Einsele H., Roosnek E., Rufer N., Sinzger C., Riegler S., Loffler J., Grigoleit U., Moris A., Rammensee H.G., Kanz L., Kleihauer A., Frank F., Jahn G., and Hebart H. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99 (2002) 3916-3922
20. Firat H., Cochet M., Rohrlich P.S., Garcia-Pons F., Darche S., Danos O., Lemonnier F.A., and Langlade-Demoyen P. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. 14 (2002) 925-934
21. Gallez-Hawkins G., Thao L., Lacey S.F., Martinez J., Li X., Franck A.E., Lomeli N.A., Longmate J., Diamond D.J., Spielberger R., Forman S.J., and Zaia J.A. Cytomegalovirus immune reconstitution occurs in recipients of allogeneic hematopoietic cell transplants irrespective of detectable cytomegalovirus infection. Biol. Blood Marrow Transplant. 11 (2005) 890-902
22. Ghanekar S.A., Nomura L.E., Suni M.A., Picker L.J., Maecker H.T., and Maino V.C. Gamma interferon expression in CD8(+) T cells is a marker for circulating cytotoxic T lymphocytes that recognize an HLA A2-restricted epitope of human cytomegalovirus phosphoprotein pp65. Clin. Diagn. Lab. Immunol. 8 (2001) 628-631
23. Gilbert M.J., Riddell S.R., Li C.R., and Greenberg P.D. Selective interference with class I major histocompatibility complex presentation of the major immediate-early protein following infection with human cytomegalovirus. J. Virol. 67 (1993) 3461-3469
24. Gilbert M.J., Riddell S.R., Plachter B., and Greenberg P.D. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 383 (1996) 720-722
25. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., Keating S.M., Berthoud T., Webster D., McShane H., and Hill A.V. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24 (2006) 4554-4561
26. Gomez C.E., Najera J.L., Jimenez E.P., Jimenez V., Wagner R., Graf M., Frachette M.J., Liljestrom P., Pantaleo G., and Esteban M. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B. Vaccine 25 (2007) 2863-2885
27. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., Pinheiro S., Gillespie G., Brown D., Loach V., Roberts J., Guimaraes-Walker A., Hayes P., Loughran K., Smith C., De Bont J., Verlinde C., Vooijs D., Schmidt C., Boaz M., Gilmour J., Fast P., Dorrell L., Hanke T., and McMichael A.J. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T-cell epitopes. J. Virol. 80 (2006) 4717-4728
28. Gratama J.W., van Esser J.W., Lamers C.H., Tournay C., Lowenberg B., Bolhuis R.L., and Cornelissen J.J. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98 (2001) 1358-1364
29. Gyulai Z., Endresz V., Burian K., Pincus S., Toldy J., Cox W.I., Meri C., Plotkin S., and Berencsi K. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-Specific CTLs. J. Infect. Dis. 181 (2000) 1537-1546
30. Hammarlund E., Lewis M.W., Hansen S.G., Strelow L.I., Nelson J.A., Sexton G.J., Hanifin J.M., and Slifka M.K. Duration of antiviral immunity after smallpox vaccination. Nat. Med. 9 (2003) 1131-1137
31. Hanke T., McMichael A.J., Dennis M.J., Sharpe S.A., Powell L.A., Mcloughlin L., and Crome S.J. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23 (2005) 1507-1514
32. Johnson R.A., Yurochko A.D., Poma E.E., Zhu L., and Huang E.S. Domain mapping of the human cytomegalovirus IE1-72 and cellular p107 protein-protein interaction and the possible functional consequences. J. Gen. Virol. 80 Pt 5 (1999) 1293-1303
33. Kern F., Surel I.P., Faulhaber N., Frommel C., Schneider-Mergener J., Schonemann C., Reinke P., and Volk H.D. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J. Virol. 73 (1999) 8179-8184
34. Khan N., Cobbold M., Keenan R., and Moss P.A. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J. Infect. Dis. 185 (2002) 1025-1034
35. Khan N., Bruton R., Taylor G.S., Cobbold M., Jones T.R., Rickinson A.B., and Moss P.A. Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes. J. Virol. 79 (2005) 2869-2879
36. Khan N., Best D., Bruton R., Nayak L., Rickinson A.B., and Moss P.A. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J. Immunol. 178 (2007) 4455-4465
37. Khanna R., and Diamond D.J. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol. Med. 12 (2006) 26-33
38. La Rosa C., Krishnan R., Markel S., Schneck J.P., Houghten R., Pinilla C., and Diamond D.J. Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries. Blood 97 (2001) 1776-1786
39. La Rosa C., Wang Z., Lacey S.F., Lalimarmo M.M., Krishnan A., Longmate J., and Diamond D.J. In vitro expansion of polyclonal T-cell subsets for adoptive immunotherapy by recombinant modified vaccinia Ankara. Exp. Hematol. 34 (2006) 497-507
40. La Rosa C., Limaye A.P., Krishnan A., Longmate J., and Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J. Infect. Dis. 195 (2007) 633-644
41. Lacey S.F., La Rosa C., Zhou W., Sharma M.C., Martinez J., Krishnan A., Gallez-Hawkins G., Thao L., Longmate J., Spielberger R., Forman S.J., Limaye A., Zaia J.A., and Diamond D.J. Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients. J. Infect. Dis. 194 (2006) 1410-1421
42. Lemonnier F.A. The utility of H-2 class I knockout mice. Virus Res. 82 (2002) 87-90
43. Limaye A.P., Bakthavatsalam R., Kim H.W., Randolph S.E., Halldorson J.B., Healey P.J., Kuhr C.S., Levy A.E., Perkins J.D., Reyes J.D., and Boeckh M. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 81 12 (2006) 1645-1652
44. Ljungman P., Perez-Bercoff L., Jonsson J., Avetisyan G., Sparrelid E., Aschan J., Barkholt L., Larsson K., Winiarski J., Yun Z., and Ringden O. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica 91 (2006) 78-83
45. Longmate J., York J., La Rosa C., Krishnan R., Zhang M., Senitzer D., and Diamond D.J. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics 52 (2001) 165-173
46. Maecker H.T., Moon J., Bhatia S., Ghanekar S.A., Maino V.C., Payne J.K., Kuus-Reichel K., Chang J.C., Summers A., Clay T.M., Morse M.A., Lyerly H.K., DeLaRosa C., Ankerst D.P., and Disis M.L. Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol. 6 (2005) 17
47. Manley T.J., Luy L., Jones T., Boeckh M., Mutimer H., and Riddell S.R. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T-cell response in natural infection. Blood 104 (2004) 1075-1082
48. Mayr A., and Danner K. Vaccination against pox diseases under immunosuppressive conditions. Dev. Biol. Stand. 41:225-34 (1978) 225-234
49. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen.Virol. 72 Pt 5 (1991) 1031-1038
50. Moorthy V.S., Pinder M., Reece W.H., Watkins K., Atabani S., Hannan C., Bojang K., McAdam K.P., Schneider J., Gilbert S., and Hill A.V. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults. J. Infect. Dis. 188 (2003) 1239-1244
51. Morello C.S., Cranmer L.D., and Spector D.H. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J. Virol. 74 (2000) 3696-3708
52. Pascolo S., Bervas N., Ure J.M., Smith A.G., Lemonnier F.A., and Perarnau B. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J. Exp. Med. 185 (1997) 2043-2051
53. Pass R.F., Fowler K.B., Boppana S.B., Britt W.J., and Stagno S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J. Clin.Virol. 35 (2006) 216-220
54. Peters B., and Sette A. Integrating epitope data into the emerging web of biomedical knowledge resources. Nat. Rev. Immunol. 7 (2007) 485-490
55. Peters B.S., Jaoko W., Vardas E., Panayotakopoulos G., Fast P., Schmidt C., Gilmour J., Bogoshi M., Omosa-Manyonyi G., Dally L., Klavinskis L., Farah B., Tarragona T., Bart P.A., Robinson A., Pieterse C., Stevens W., Thomas R., Barin B., McMichael A.J., McIntyre J.A., Pantaleo G., Hanke T., and Bwayo J. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25 (2007) 2120-2127
56. Plachter B., Britt W., Vornhagen R., Stamminger T., and Jahn G. Analysis of proteins encoded by IE regions 1 and 2 of human cytomegalovirus using monoclonal antibodies generated against recombinant antigens. Virology 193 (1993) 642-652
57. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J. Virol. 74 (2000) 7651-7655
58. Reddehase M.J., Mutter W., Munch K., Buhring H.J., and Koszinowski U.H. CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J. Virol. 61 (1987) 3102-3108
59. Rochlitz C., Figlin R., Squiban P., Salzberg M., Pless M., Herrmann R., Tartour E., Zhao Y., Bizouarne N., Baudin M., and Acres B. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5 (2003) 690-699
60. Rohrlich P.S., Cardinaud S., Firat H., Lamari M., Briand P., Escriou N., and Lemonnier F.A. HLA-B*0702 transgenic, H-2KbDb double-knockout mice: phenotypical and functional characterization in response to influenza virus. Int. Immunol. 15 (2003) 765-772
61. Rohrlich P.S., Cardinaud S., Lule J., Montero-Julian F.A., Prodhomme V., Firat H., Davignon J.L., Perret E., Monseaux S., Necker A., Michelson S., Lemonnier F.A., Charneau P., and Davrinche C. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex vivo stimulation and expansion of CD8(+) cytotoxic T cells from human peripheral blood cells. Hum. Immunol. 65 (2004) 514-522
62. Schleiss M.R., Lacayo J.C., Belkaid Y., McGregor A., Stroup G., Rayner J., Alterson K., Chulay J.D., and Smith J.F. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. J. Infect. Dis. 195 (2007) 789-798
63. Sinclair E., Black D., Epling C.L., Carvidi A., Josefowicz S.Z., Bredt B.M., and Jacobson M.A. CMV antigen-specific CD4+ and CD8+ T cell IFNgamma expression and proliferation responses in healthy CMV-seropositive individuals. Viral Immunol. 17 (2004) 445-454
64. Sinclair E., Tan Q.X., Sharp M., Girling V., Poon C., Natta M.V., Jabs D.A., Inokuma M., Maecker H.T., Bredt B., and Jacobson M.A. Protective immunity to cytomegalovirus (CMV) retinitis in AIDS is associated with CMV-specific T cells that express interferon-gamma and interleukin-2 and have a CD8+ cell early maturational phenotype. J. Infect. Dis. 194 (2006) 1537-1546
65. Song G.Y., Gibson G., Haq W., Huang E.C., Srivasta T., Hollstein M., Daftarian P., Wang Z., Diamond D., and Ellenhorn J.D. An MVA vaccine overcomes tolerance to human p53 in mice and humans. Cancer Immunol. Immunother. 56 (2007) 1193-1205
66. Stittelaar K.J., Kuiken T., de Swart R.L., van Amerongen G., Vos H.W., Niesters H.G., van Schalkwijk P., van der K.T., Wyatt L.S., Moss B., and Osterhaus A.D. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine 19 (2001) 3700-3709
67. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., Sleath P.R., Grabstein K.H., Hosken N.A., Kern F., Nelson J.A., and Picker L.J. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202 (2005) 673-685
68. Vaz-Santiago J., Lule J., Rohrlich P., Kravtzoff R., Le Roy E., Davignon J.L., Betbeder D., and Davrinche C. IE1-pp65 recombinant protein from human CMV combined with a nanoparticulate carrier, SMBV, as a potential source for the development of anti-human CMV adoptive immunotherapy. Cytotherapy 4 (2002) 11-19
69. Walter E.A., Greenberg P.D., Gilbert M.J., Finch R.J., Watanabe K.S., Thomas E.D., and Riddell S.R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 333 (1995) 1038-1044
70. Wang Z., La Rosa C., Maas R., Ly H., Brewer J., Mekhoubad S., Daftarian P., Longmate J., Britt W.J., and Diamond D.J. Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus. J. Virol. 78 (2004) 3965-3976
71. Wang Z., La Rosa C., Mekhoubad S., Lacey S.F., Villacres M.C., Markel S., Longmate J., Ellenhorn J.D., Siliciano R.F., Buck C., Britt W.J., and Diamond D.J. Attenuated poxviruses generate clinically relevant frequencies of CMV-specific T cells. Blood 104 (2004) 847-856
72. Wang Z., La Rosa C., Li Z., Ly H., Krishnan A., Martinez J., Britt W.J., and Diamond D.J. Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1. Vaccine 25 (2007) 1132-1141
73. White E.A., Del Rosario C.J., Sanders R.L., and Spector D.H. The IE2 60-kilodalton and 40-kilodalton proteins are dispensable for human cytomegalovirus replication but are required for efficient delayed early and late gene expression and production of infectious virus. J. Virol. 81 (2007) 2573-2583
74. Wills M.R., Carmichael A.J., Mynard K., Jin X., Weekes M.P., Plachter B., and Sissons J.G. The human CTL response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T cell receptor usage of pp65-specific CTL. J. Virol. 70 (1996) 7569-7579
75. Wyatt L.S., Earl P.L., Liu J.Y., Smith J.M., Montefiori D.C., Robinson H.L., and Moss B. Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res. Hum. Retrovir. 20 (2004) 645-653
76. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., and Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J. Virol. 77 (2003) 799-803
77. Yue Y., Kaur A., Eberhardt M.K., Kassis N., Zhou S.S., Tarantal A.F., and Barry P.A. Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques. J. Virol. 81 (2007) 1095-1109
78. Yue Y., Wang Z., Abel K., Li J., Strelow L., Mandarino A., Eberhardt M.K., Schmidt K.A., Diamond D.J., and Barry P.A. Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques. Med. Microbiol. Immunol. 197 (2008) 117-123
79. Zaia J.A. Prevention and management of CMV-related problems after hematopoietic stem cell transplantation. Bone Marrow Transplant. 29 (2002) 633-638
80. Zaia, J.A., Sissons, J.G., Riddell, S.R., and Diamond, D.J., Status of cytomegalovirus prevention and treatment in 2000. Hematology 2000, 339-355. 2001.
81. Zhang X., Cassis-Ghavami F., Eller M., Currier J., Slike B.M., Chen X., Tartaglia J., Marovich M., and Spearman P. Direct comparison of antigen production and induction of apoptosis by canarypox virus- and modified vaccinia virus ankara-human immunodeficiency virus vaccine vectors. J. Virol. 81 (2007) 7022-7033